Triple Negative Breast Cancer and 68 Ga-Trivehexin : A Glance of Hope.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40369806.
- Also identified by DOI 10.1097/RLU.0000000000005963.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
αvβ6 integrin is a heterodimeric transmembrane cell adhesive receptors that mediate cell-substratum adhesion and has been correlated to aggressiveness of various malignancies including breast cancer, with reduced progression-free survival. This integrin was found to facilitate tumor invasion, inhibit apoptosis, regulate expression of matrix metalloproteases, and activate TGF-β. Therefore, it could serve as a prognostic prob for tracking preinvasive tumor progression and monitoring the treatment variety of radiopharmaceuticals that target αvβ6-integrin, as well as its potential role as theranostic agent. Our case demonstrates the viability of 68 Ga-Trivehexin PET tracer in a case of histopathologically proven triple-negative breast cancer.
Medical subject headings
- Gallium Radioisotopes
- Triple Negative Breast Neoplasms